Does Graded Prognostic Assessment outperform Recursive Partitioning Analysis in patients with moderate prognosis brain metastases? by Estabrook, Neil C. et al.
69ISSN 2045-0907CNS Oncol. (2016) 5(2), 69–76
part of
CNS Oncology
10.2217/cns.15.45 © 2016 Future Medicine Ltd
ReseaRch aRticle
Does Graded Prognostic Assessment 
outperform Recursive Partitioning 
Analysis in patients with moderate 
prognosis brain metastases?
Neil C Estabrook*,1, Stephen T Lutz2, Cynthia S Johnson3, Simon S Lo4 
& Mark A Henderson1
1Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN, USA 
2Blanchard Valley Regional Cancer Center, Findlay, OH, USA 
3Department of Biostatistics, Indiana University School of Medicine, Indianapolis, IN, USA 
4University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA 
*Author for correspondence: Tel.: +1 317 944 2524; Fax: +1 317 944 2486; ncestabr@iupui.edu
aim: To compare the clinical utility of the Recursive Partitioning Analysis (RPA) and Graded 
Prognostic Assessment (GPA) in predicting outcomes for moderate prognosis patients with 
brain metastases. Methods & materials: We reviewed 101 whole brain radiotherapy cases. 
RPA and GPA were calculated. Overall survival was compared. Results: Sixty-eight patients 
had moderate prognosis. RPA patient characteristics for increased death hazard were ≤10 
WBRT fractions or no surgery/radiosurgery. GPA patients had increased death risk with no 
surgery/radiosurgery or lower Karnofsky Performance Status. conclusion: The indices have 
similar predicted survival. Patients scored by RPA with longer radiation schedules had longer 
survival; patients scored by GPA did not. This indicates GPA is more clinically useful, leaving 
less room for subjective treatment choices.
First draft submitted: 18 September 2015; Accepted for publication: 19 November 2015; 
Published online: 17 March 2016
Practice points
 ●  Optimal treatment for moderate prognosis patients (Recursive Partitioning Analysis [RPA] II or Graded Prognostic 
Assessment [GPA] 1.5–2.5) can be unclear.
 ●  Treatment options for brain metastases include surgery, stereotactic radiosurgery, whole brain radiotherapy (WBRT), 
supportive measures or combinations of these modalities.
 ●  Better prognosis patients are often prescribed longer schedules of whole brain radiation.
 ●  On multivariable analysis among RPA II patients, receiving >10 WBRT fractions or undergoing surgery/stereotactic 
radiosurgery were significantly associated with increased survival.
 ●  Among patients with GPA 1.5–2.5, better Karnofsky Performance Status or undergoing surgery/stereotactic 
radiosurgery were significantly associated with increased survival.
 ●  The RPA II and GPA 1.5–2.5 have similar predicted median survivals (4.2 and 3.8 months), and in our patient group 
those scored by the RPA and assigned a longer radiation schedule had a survival advantage, while patients scored by 
the GPA did not.
 ●  This could indicate the GPA is more clinically useful, leaving less room for subjective assessment in choosing 
treatment.
 ●  There are many recently published articles concerning prognostic indices for brain metastases which are succinctly 
summarized in tables 5 and 6 of this publication.
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Over 170,000 cases of brain metastases are diag-
nosed in the USA each year, and the length of 
survival for these patients is often limited [1]. 
The Radiation Therapy Oncology Group 
Recursive Partitioning Analysis (RPA) and 
Graded Prognostic Assessment (GPA) are prog-
nostic indices validated to predict survival and 
guide treatment for these patients [2–5]. These 
indices were formulated by comparing survival 
to patient characteristics compiled from brain 
metastasis treatment protocols across three 
decades.
The RPA has three classes of patients enu-
merated as ‘I’, ‘II’ and ‘III,’ with class I having 
the longest predicted survival and class III the 
shortest. The RPA classes are based upon age, 
Karnofsky performance status (KPS), control of 
the primary tumor and evidence of extracranial 
metastases (table 1) [2]. The GPA has four classes 
with a score that may be considered analogous 
to a student’s grade point average in school. The 
classes are arranged from best to worst prognosis 
as follows: 3.5 to 4.0, 3.0, 1.5–2.5 and 0.0–1.0. 
The GPA employs criteria that are slightly dif-
ferent than those used in the RPA, estimating 
survival by age, performance status, number of 
brain metastases and extracranial metastases 
(table 2) [4].
Treatment options for brain metastases include 
surgery, stereotactic radiosurgery (SRS), whole 
brain radiation therapy (WBRT), supportive 
measures or combinations of these modalities. 
The median survival (MS) of the worst progno-
sis patients is estimated by the RPA and GPA to 
be 2.3 and 2.6 months respectively [2,4]. In these 
patients, treatments are usually less aggressive 
and typically include WBRT and/or steroids. 
The best fractionation scheme is not well estab-
lished, but there are many who favor shorter 
courses or supportive care only [6–8].
More aggressive treatment may produce better 
outcomes in good prognosis patients. There are 
data showing a survival advantage for patients 
with a single brain metastasis who receive 
surgery or SRS in addition to WBRT [9,10]. A 
recently reported meta-analysis of randomized 
trials of SRS ± WBRT in RPA I or II patients 
with one to four brain metastases revealed that, 
in patients ≤50 years old, survival was signifi-
cantly better with SRS alone [11]. This is cur-
rently not the standard of care [12,13], but may 
affect future guidelines.
With ‘moderate prognosis’ patients (RPA II 
or GPA 1.5–2.5), treatment options become 
more variable. For these patients, the MS is 4.2 
months for RPA II and 3.8 months for GPA 
1.5–2.5 patients. Selecting the best treatment 
for patients in these categories is challenging, 
and there have been changes suggested to both 
the GPA and RPA to add more granularity. 
Specifically, Sperduto et al. have created the 
‘Diagnosis Specific-GPA’ (DS-GPA) where the 
GPA score is adjusted based on the primary 
disease histology [5]. Similarly, Yamamoto et al. 
have published recommendations to subdivide 
the RPA II into three subgroups that represent 
the range of MS lengths within this group [14].
In our clinic, moderate prognosis patients 
who are expected to have more favorable out-
comes based on their initial presentation will 
frequently receive more aggressive treatment for 
their brain metastases such as protracted WBRT 
regimens (generally 35–37.5 Gy in 14–15 frac-
tions) with or without surgery or SRS. We were 
interested in evaluating the median survival 
in the patients who had moderate prognosis 
(RPA II or GPA 1.5–2.5). The objective of this 
study was to evaluate whether either the GPA 
or the RPA provided more useful guidance to 
clinicians. Here we retrospectively analyze 101 
consecutive patients with brain metastases that 
had undergone WBRT, measured their survival 
in a nonprotocol setting and compared actual 
survival to that predicted by the RPA and GPA 
indices.
Materials & methods
Following study approval by our institutional 
review board, the charts of all consecutive 
brain metastasis patients treated with WBRT 
table 1. Recursive partitioning analysis.
class Patient characteristics Ms (months)
I KPS ≥ 70, age < 65, no extracranial mets, controlled primary 7.1
II All others, that is KPS ≥70 and at least one of the following: age ≥ 65 or 
extracranial mets or uncontrolled primary
4.2
III KPS < 70 2.3
KPS: Karnofsky performance status; Mets: Metastases, MS: Median survival; RPA: Recursive Partitioning Analysis.
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between August 2008 and September 2010 were 
reviewed. Reasons for exclusion from the study 
included primary brain tumors, <19 years old, 
diagnosis of multiple myeloma/leukemia/lym-
phoma, retreatment with WBRT and patients 
without evidence of parenchymal brain disease 
(i.e., leptomeningeal metastases, prophylactic 
treatment).
The inclusion criteria were met by 101 
patients. A retrospective chart review collected 
the data for calculating each patient’s RPA and 
GPA (tables 1 & 2) as well as treatment details, 
including corticosteroid use and surgery and/or 
SRS. All patients had received MRIs. We based 
the number of brain metastases on the MRI 
report rather than review of MRI images. For 13 
patients, KPS had to be retrospectively assigned 
from the radiation oncologist’s consult note in 
cases where no KPS had been explicitly stated. 
For these, chart notes were examined for patient 
characteristics and exam findings to assign a 
KPS value. For five patients, KPS was converted 
from another performance status scale. To cal-
culate survival time, the social security death 
table 2. Graded prognostic assessment.
Patient characteristics GPa score
0 0.5 1.0
Age ≥60 50–59 <50
KPS <70 70–80 90–100
CNS mets (n) >3 2–3 1
Extra-cranial mets Present – Absent
GPa grade (sum of GPa scores)  Ms (months) 
3.5–4 11.0
3 6.9
1.5–2.5 3.8
0–1 2.6
GPA: Graded Prognostic Assessment; KPS: Karnofsky performance status; Mets: Metastases; MS: Median survival.
table 3. Patient, disease and treatment characteristics.
  all patients (n = 101) RPa ii (n = 68) GPa 1.5–2.5 (n = 61)
  Mean Range Mean Range Mean Range
Age 57.4 (31–82) 56.0 (38–82) 54.9 (31–82)
KPS 74.3 (50–100) 80.4 (70–100) 78.0 (50–100)
  n  %  n % n %
Male 47 46.5 35 51.5 27 44.3
Female 54 53.5 33 48.5 34 55.7
Histology:            
NSCLC 47 46.5 26 38.2 26 42.6
Melanoma 12 11.9 12 17.6 8 13.1
Breast 12 11.9 7 10.3 6 9.8
SCLC 9 8.9 6 8.8 7 11.5
Other 21 20.8 17 25.0 14 23.0
Number CNS mets:            
– 1 19 18.8 11 16.2 14 23.0
– 2–3 36 35.6 24 35.3 25 41.0
– >3 46 45.5 33 48.5 22 36.0
Number of fractions:            
– ≤10 60 59.4 37 54.4 34 55.7
– >10 41 40.6 31 45.6 27 44.3
Surgery or SRS 32 31.7 22 32.4 23 37.7
There is overlap between RPA II and GPA 1.5–2.5 patients.
GPA: Graded Prognostic Assessment; KPS: Karnofsky performance status; Mets: Metastases; NSCLC: Non-small-cell lung cancer; 
RPA: Recursive Partitioning Analysis; SCLC: Small-cell lung cancer; SRS: Stereotactic radio surgery.
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index was used for date of death or ongoing 
survival.
statistical methods
Each patient was assigned an RPA and GPA 
score and was then grouped by those. Survival 
was calculated from the time of the WBRT con-
sult date. MS was calculated using the Kaplan–
Meier method. The associations of the categori-
cal variables of RPA class and GPA grade with 
overall survival were examined with a log–rank 
test. Univariate Cox-proportional hazards mod-
els were done among patients with RPA II and 
also GPA 1.5–2.5 to investigate the association 
between sex, histology (NSCLC, melanoma, 
breast, SCLC, other), inclusion of surgery/SRS, 
number of CNS metastases (1, 2–3, >3), num-
ber of fractions (≤10 vs >10), age and KPS with 
overall survival. Multivariable Cox proportional 
hazards models were fit including all factors with 
univariate p-value <0.25. A backward selection 
approach was used to determine the final model.
Results
The mean (±SD) patient age was 57.4 (±10.6) 
years. Fifty-three percent were female (54 of 
101). Forty-seven percent had NSCLC (47 of 
101) and 12% each had melanoma and breast 
cancer (12 of 101 respectively). Patient and 
disease characteristics are shown in table 3.
Of the 101 cases, the number that fit the 
RPA I, II and III classes were 8, 68 and 25 
patients, respectively. The 68 RPA II patients 
in this study showed a median survival of 4.8 
months (95% CI: 3.5–6.0 months). The pre-
dicted median survival of 4.2 months per the 
RTOG RPA falls within the 95% CI in our 
dataset.
All patients were also grouped according to 
the GPA index. This analysis showed that 2, 3, 
61 and 35 patients resided in the 4 GPA classes; 
3.5–4.0, 3.0, 1.5–2.5 and 0.0–1.0, respectively. 
For the 61 patients in the GPA 1.5–2.5, the 
median survival was 5.0 months (95% CI: 
4.3–8.0). In this case, the predicted MS of 3.8 
table 4. Univariate survival.
  hazard ratio (95% ci) p-value
RPA II 
Age (increase of 10 years) 1.47 (1.10–1.97) 0.0095
KPS (decrease of 5 points) 1.20 (1.02–1.41) 0.0321
Sex (male vs female) 1.94 (1.11–3.40) 0.0204
Histology:   0.5432
– Breast vs NSCLC 0.57 (0.19–1.67)  
– Melanoma vs NSCLC 1.06 (0.47–2.33)  
– SCLC vs NSCLC 1.75 (0.69–4.41)  
Number CNS mets:    
– 2–3 vs 1 1.85 (0.74–4.67) 0.2035
– >3 vs 1 2.25 (0.92–5.52)  
Number of fractions (≤10 vs >10) 2.51 (1.40–4.47) 0.0019
Surgery or SRS (no vs yes) 4.74 (2.31–9.71) <0.0001
GPA 1.5–2.5 
Age (increase of 10 years) 1.20 (0.88–1.63) 0.2553
KPS (decrease of 5 points) 1.21 (1.08–1.36) 0.0015
Sex (male vs female) 1.35 (0.75–2.41) 0.3184
Histology:   0.1454
– Breast vs NSCLC 0.41 (0.12–1.37)  
– Melanoma vs NSCLC 0.75 (0.28–2.01)  
– SCLC vs NSCLC 2.19 (0.91–5.29)  
Number CNS mets:    
– 2–3 vs 1 0.85 (0.41–1.73) 0.5985
– >3 vs 1 0.67 (0.31–1.46)  
Number of fractions (≤10 vs >10) 1.89 (1.04–3.43) 0.0373
Surgery or SRS (no vs yes) 2.83 (1.48–5.43) 0.0017
GPA: Graded Prognostic Assessment; KPS: Karnofsky performance status; Mets: Metastases; NSCLC: Non-small-cell lung cancer; 
RPA: Recursive Partitioning Analysis; SCLC: Small-cell lung cancer; SRS: Stereotactic radio surgery.
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months per the GPA index is outside the 95% 
CI of the actual MS in our dataset.
Survival varied significantly according to 
prognostic class. The survival of patients in RPA 
I versus II versus III was significantly different 
(MS 7.1, 4.8 and 2.4 months, respectively, p = 
0.0016). Survival significantly differed by GPA 
grade (MS not yet achieved, 5.0 and 2.4 months 
for GPA grades 3.0–4.0, 1.5–2.5 and 0.0–1.0, 
respectively, p < 0.0001).
A total of 84 patients were in either the RPA 
II or the GPA 1.5–2.5 group. Forty-five patients 
were in both groups. Twenty-three patients were 
in the RPA II group only (four were GPA 3.0–4.0 
and 19 were GPA 0.5–1.0) and 16 patients were 
in the GPA 1.5–2.5 group only (seven were RPA 
I and nine were RPA III). The RPA II only and 
GPA 1.5–2.5 only groups were similar on age, 
sex, histology, number of fractions and surgery 
(all p > 0.2). Patients who were only in the RPA 
II group had significantly higher KPS scores 
than patients who were only in the GPA 1.5–2.5 
group (mean KPS: 76.7 [±7.9] vs 65.9 [±14.5], 
two-sample t-test p = 0.0131). Also, a greater pro-
portion of RPA II only patients had more than 
three CNS metastases compared with patients 
who were only in the GPA 1.5–2.5 group (60.9 
vs 18.8%, Mantel-Haenszel χ2 p = 0.0106).
On univariate analysis in the RPA II group, 
increased survival was associated with being 
younger, having better KPS, female, treated 
with >10 fractions and undergoing surgery/SRS. 
In the GPA 1.5–2.5 group, having better KPS, 
being treated with >10 fractions and undergoing 
surgery/SRS were associated with significantly 
longer survival (table 4).
table 5. Recently published work concerning prognostic indices for brain metastases.
study (year) Patients included Goal of study Results Ref.
Sperduto et al. (2012)  3940 patients Concise update on the DS-GPA for easier 
clinical use
There is heterogeneity of prognosis that 
varies by primary tumor type
[28]
Sperduto et al. (2012) 400 patients with breast 
cancer primaries
Refine the breast DS-GPA by analyzing a 
larger cohort by tumor subtype
There is a wide variation in prognosis for 
breast tumor subtypes
[29]
Yamamoto et al. (2013) 4608 patients, Treated 
with GK
Comparing MS in the newly proposed 
Modified RPA-II to the DS-GPA for five 
histologies
Modified RPA-II is valid for all five 
histologies. The predicted MS 
differences were only valid with NSCLC 
primary in the DS-GPA index for this 
patient group
[32]
Yamamoto et al. (2012) 3753 patients treated 
with GK
Finding subclasses within the existing 
RPA-II group for better prognostic value
Created three subclasses within the RPA-
II based on KPS, primary tumor control, 
number of brain mets, extra cranial mets
[14]
Serizawa et al. (2012) 2445 patients treated 
with GK
Comparing RPA, SIR, BSBM, GPA and 
Modified RPA-II for OS and QS
A better prognostic systems is needed 
for predicting QS
[27]
Bernholts-Slamen et al. 
(2012)
2367 patients from 
seven previous RTOG 
brain mets trials
Creating a new nomogram for prognosis Index using primary histology, status of 
primary, extracranial mets, age, KPS and 
number of brain mets
[23]
Rodrigues et al. (2013) 501 patients treated 
with LINAC-based SRS 
or fractionated SRT
Comparing the usefulness of several 
validated indices using traditional and 
novel statistical metrics
RPA, GGS, RADES I and RDAM indices 
were superior in more than one metric. 
No index has clear superiority over 
RPA. GPA is the best for classifying poor 
prognosis
[26]
Viani et al. (2012) 412 patients treated 
with WBRT
Comparing GPA, RPA, BSBM, RDAM and 
Germany Score (RADES I) via a neural 
network
GPA is most powerful at predicting 
survival in the indices compared
[30]
Buglione et al. (2012) 382 patients treated 
with WBRT
Analyzing OS with the RPA index with 
respect to primary tumor histology
Primary histology is significant for OS in 
RPA I and II, but not III
[24]
Villa et al. (2011) 285 patients Prospective analysis to validate the GPA GPA is a valid index, as prognostic as 
RPA and BSBM
[31]
Likhacheva et al. (2012) 251 patients treated 
with SRS
Comparing RPA to the DS-GPA DS-GPA is better for stratifying to 
treatment types
[25]
BSBM: Basic System for brain metastases; DS-GPA: Diagnosis specific-GPA; GGS: Golden grading system; GK: Gamma knife; GPA: Graded Prognostic Assessment; KPS: Karnofsky 
performance status; LINAC: Linear Accelerator; Mets: Metastases; MS: Median survival; NSCLC: Non-small-cell lung cancer; OS: Overall survival; QS: Quality of life survival; 
RADES I: Rades; et al. first index; RDAM: Rotterdam index; RPA: Recursive Partitioning Analysis; SIR: Score Index for Radiosurgery; SRS: Stereotactic radio surgery; SRT: Stereotactic 
radiation therapy; WBRT: Whole-brain radiation therapy.
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On multivariable analysis among RPA II 
patients, receiving >10 fractions and undergoing 
surgery/SRS were significantly associated with 
increased survival. Patients receiving ≤10 frac-
tions had an hazard ratio (HR) of 2.45 (95% CI: 
1.35–4.44) with increased risk of death compared 
with patients receiving >10 fractions (p = 0.0033). 
Patients who did not undergo surgery/SRS 
had an HR of 4.76 (95% CI: 2.28–9.95) with 
increased risk of death compared with patients 
who did undergo surgery/SRS (p < 0.0001). 
Among patients with GPA 1.5–2.5, better KPS 
and undergoing surgery/SRS were significantly 
associated with increased survival on multivari-
able analysis. Every 5-point decrease in KPS was 
associated with an HR of 1.20 for an increase in 
risk of death (95% CI: 1.07–1.35; p = 0.0020). 
Patients who did not undergo surgery/SRS had an 
HR of 2.78 (95% CI: 1.44–5.35) with increased 
risk of death compared with patients who did 
undergo surgery/SRS (p = 0.0022). However, 
number of fractions received was not statistically 
significant in the final multivariable model for 
patients in the GPA 1.5–2.5 group. If number 
of fractions is included in the model, along with 
KPS and surgery/SRS, the hazard ratio is 1.63 
(95% CI: 0.88–3.01; p = 0.1192).
Discussion
Our data show that all moderate prognosis 
patients who received surgery or SRS tended to 
have a survival advantage versus those who did 
not. This finding is well supported in the litera-
ture and is understood to be due more to patient 
selection than to the treatment choice [15–17].
Our analysis found that decreasing KPS was 
a hazard to survival for patients in the GPA 
1.5–2.5 group, but not for patients in the RPA 
II group. This is likely because all patients in 
the RPA II category must have a relatively tight 
window of possible KPS values with a KPS ≥70. 
In the GPA 1.5 to 2.5 group KPS (a known inde-
pendent predictor of survival) can be variable 
anywhere from 10 to 100 based on how the 
other three patient characteristics compromis-
ing the GPA are scored (tables 1 & 2). Therefore, 
by definition of how the GPA is calculated, a 
continuum of patient outcomes in part related 
to the patient’s KPS could be observed.
In the patients studied, RPA class and GPA 
scores were retrospectively assigned for this 
analysis. At the time of consultation, clinicians 
prescribed more or less aggressive WBRT frac-
tionation schedules based on perceived progno-
sis. Patients assigned to the intermediate risk 
group with the RPA have a survival advantage 
with more aggressive WBRT fractionation (>10), 
but no such advantage was seen in the GPA inter-
mediate risk group. As the number of treatment 
fractions should not be part of a prognostic sys-
tem for estimating survival, this finding may 
indicate that the GPA is more helpful than the 
RPA for guiding clinicians’ treatment decisions 
for moderate prognosis patients. There is per-
haps too much variability in prognosis within 
the ‘catch all’ RPA II subgroup, leaving room for 
MS to be affected by more or less aggressive treat-
ment decisions. The GPA is more granular by 
nature and does not seem to have this drawback.
Multiple prognostic indices exist for patients 
with brain metastases. We evaluated the RPA 
and the GPA, but some other commonly 
employed indices are: the DS-GPA, Score 
Index for Radiosurgery (SIR), Basic System for 
Brain Metastases (BSBM), RADES, Rotterdam 
score (RDAM) and Golden Grading System 
(GGS) [2,4,5,18–22]. table 5 lists the factors con-
sidered when employing these prognostic guides.
table 6. comparison of prognostic indices used for survival in patients with brain metastases.
index name  characteristics included
RPA KPS, age, controlled primary, extra cranial mets
GPA KPS, age, number of brain mets, extra cranial mets
DS-GPA Same as above but also considers primary histology
SIR KPS, age, extra cranial mets, number of brain mets, largest brain met volume, site in 
brain, WBRT
BSBM KPS, controlled primary, extra cranial mets
RADES-I KPS, age, extra cranial mets, interval until WBRT
RDAM KPS, response to steroids, systemic disease
GGS KPS, age, extra cranial mets
BSBM: Basic System for Brain Metastases; DS-GPA: Diagnosis Specific-GPA; GGS: Golden Grading System; GPA: Graded Prognostic 
Assessment; KPS: Karnofsky performance status; Mets: Metastases; RADES I: Rades et al. first index; RDAM: Rotterdam index; 
RPA: Recursive Partitioning Analysis; SIR: Score Index for Radiosurgery; WBRT: Whole-brain radiation therapy.
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The impetus for our study was our desire to 
help select the most appropriate treatment for 
our patients. Our dilemma was in selecting the 
most reliable, easy to use prognostic guideline. 
Several recent studies have been published with 
this same goal in mind (table 6) [14,23–32].
The DS-GPA [28,29] has proved to be more 
granular than previous systems, but our popula-
tion did not have enough patients of varying his-
tologies to evaluate prognosis based on histology. 
A limitation of this study was a lack of power to 
find significance in survival between histologic 
subtypes, so in our analysis we chose to use the 
GPA as initially described. Although DS-GPA 
is the most recent system used for prognostica-
tion, the RPA and GPA are still being used in the 
radiation oncology and neuro-oncology commu-
nities. The GPA has also been validated to be a 
useful prognostic system [31] and compared with 
DS-GPA, the GPA is more user friendly. Future 
studies validating the DS-GPA against the GPA 
with larger groups of patients are warranted.
While our dataset is small and this is a single-
institution retrospective study, our analysis con-
tributes to the recently published body of work 
directed at finding a better prognostic definition 
for a sometimes difficult to assess population of 
patients. The volume of recent publications on this 
topic highlights the need among clinicians for bet-
ter guidance when selecting treatment options for 
patients with metastatic brain disease when prog-
nosis is unclear. Prospective studies are needed to 
better evaluate the ability of a prognostic index 
to guide treatment and accurately predict MS, 
quality of life and local control based on patient 
characteristics. Considering our results and our 
interpretation of the recent literature on this 
topic, the GPA (and, by extension, the DS-GPA) 
seems to be a reasonable prognostic index to bring 
forward into future prospective studies.
conclusion
The objective of this study was to evaluate 
whether the GPA or the RPA provided more 
useful guidance to clinicians for estimating 
survival in patients with brain metastases 
who have moderate prognosis. Our analysis 
compares the two indices’ moderate prog-
nosis groups because optimal treatment for 
these patients (RPA II or GPA 1.5–2.5) can 
be unclear. Better prognosis patients are often 
prescribed longer schedules of whole brain 
radiation. The RPA II and GPA 1.5–2.5 have 
similar predicted median survivals (4.2 and 
3.8 months), and in our patient group, those 
scored by the RPA and assigned a longer radia-
tion schedule had a survival advantage, while 
patients scored by the GPA did not. When 
prognostic factors are ‘treatment related,’ such 
as we found in our analysis of the RPA II, fur-
ther stratification within the prognostic tool 
could be difficult. This could also indicate that 
the GPA is more clinically useful because it 
does not have this drawback, therefore leaving 
less room for a clinician’s subjective assessment 
in choosing treatment.
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